Maxacalcitol

Drug Profile

Maxacalcitol

Alternative Names: 22-oxacalcitriol; OCT; Oxarol

Latest Information Update: 24 Mar 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Chugai Pharmaceutical
  • Developer Chugai Pharmaceutical; Maruho
  • Class Antipsoriatics; Calcium regulators; Dihydroxycholecalciferols
  • Mechanism of Action Vitamin D3 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Ichthyosis; Palmoplantar keratoderma; Palmoplantar pustulosis; Psoriasis; Secondary hyperparathyroidism

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 01 Dec 2016 Chugai Pharmaceutical completes a phase I trial in Secondary hyperparathyroidism (In volunteers) in Japan and Taiwan (JapicCTI153094)
  • 04 Nov 2009 Schering-Plough has been acquired and merged into Merck & Co
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top